Tumor heterogeneity, evolution, & the immune response

 

We interrogate the genetic, cellular, and spatial heterogeneity of malignant and metastatic tumors, combining multi-color "Confetti" lineage tracing with next-gen sequencing. We are interested in how tumor heterogeneity evolves during progression and metastasis, and how distinct tumor subclones interact. We are also studying the impact of heterogeneity in tumor mutations—and neoantigens—on the anti-tumor immune response.

 
 

CONFETTI LIneage Tracing

  The "Confetti" lineage tracing system stochastically labels cells with four distinct colors, enabling us to follow distinct tumor clones over time. Above: a benign skin tumor, 3 days after labeling.

The "Confetti" lineage tracing system stochastically labels cells with four distinct colors, enabling us to follow distinct tumor clones over time. Above: a benign skin tumor, 3 days after labeling.

Sequencing AppRoaches

  Sequencing enables genetic dissection of tumor clones and identification of candidate neo-antigens. Above: Copy number alterations and mutation signature profile characteristic of DMBA carcinogen-induced skin tumors.

Sequencing enables genetic dissection of tumor clones and identification of candidate neo-antigens. Above: Copy number alterations and mutation signature profile characteristic of DMBA carcinogen-induced skin tumors.